Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 18 January 2026 - 3 February 2026

Liminatus Pharma (LIMN) jumps in premarket after late-session spike as Nasdaq $1 rule hangs over shares

Liminatus Pharma (LIMN) jumps in premarket after late-session spike as Nasdaq $1 rule hangs over shares

Liminatus Pharma shares jumped 29.4% to $0.74 in premarket trading Tuesday after surging 64.6% to $0.94 in Monday’s after-hours session. The stock remains below the $1 minimum required for Nasdaq listing, with the company facing a July 14, 2026 deadline to regain compliance. Liminatus disclosed it received a Nasdaq deficiency notice in January. Market cap stood near $15.5 million.
3 February 2026
····
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly shares rose 1.6% to $1,040.80 midday Friday after announcing a $3.5 billion injectable drug plant near Allentown, Pennsylvania, set to open by 2031. Pennsylvania will provide $100 million for the project. Lilly also signed a $1.93 billion autoimmune research deal with Repertoire. Quarterly results are due Feb. 4.
30 January 2026
·····
Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Gilead Sciences shares fell 1.3% to $139.19 Wednesday afternoon after Medicare named its HIV drug Biktarvy for 2026 price negotiations, with caps set to start in 2028. The company also reported its cancer drug Trodelvy was upgraded to “category 1” in new NCCN breast cancer guidelines. Investors await Gilead’s earnings on Feb. 10.
28 January 2026
··
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
····
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk shares rose 4.9% to $62.23 in premarket trading after new data showed U.S. prescriptions for the oral Wegovy pill jumped to 20,392 from 4,286. The surge comes as investors watch prescription trends ahead of Novo’s Feb. 4 results. Rival Eli Lilly shares edged up 0.8%. India’s Sun Pharmaceutical won approval to produce generic semaglutide after the patent expires in March.
23 January 2026
·····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
····
Eternal CEO Exit, Ozempic Generic Nod, Waaree Profit Surge: India’s Q3 Results Move Stocks

Eternal CEO Exit, Ozempic Generic Nod, Waaree Profit Surge: India’s Q3 Results Move Stocks

Eternal founder Deepinder Goyal will step down as CEO on Feb. 1, with Blinkit head Albinder Dhindsa taking over. Dr Reddy’s won approval to sell a generic Ozempic in India and plans to launch 12 million semaglutide pens in the first year. Waaree Energies more than doubled its profit, while HPCL and Bank of India also reported higher earnings for the quarter.
22 January 2026
·····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
······
Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax shares rose nearly 1% in premarket trading Wednesday after Pfizer agreed to license its Matrix-M vaccine adjuvant for up to two infectious disease programs. Pfizer will pay $30 million upfront, with potential milestones and royalties. The deal took effect January 15. Investors are pushing for more details on additional licenses and upfront payments for Q1.
21 January 2026
······
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.
21 January 2026
·····
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss, and investors are weighing two fresh signals — the speed of the U.S. drug regulator’s action, and whether pills can expand demand beyond injections. The setup is more delicate than it appears. Speeding up the timeline for a new oral
18 January 2026
······
1 2 3 … 11

Stock Market Today

Jardine Matheson stock slid 2.4% Friday — here’s what matters before Monday’s open

Jardine Matheson stock slid 2.4% Friday — here’s what matters before Monday’s open

7 February 2026
Singapore, Feb 7, 2026, 15:29 SGT — Market closed. Jardine Matheson Holdings fell 2.4% on Friday to close at $75.71 in its U.S. dollar counter on the Singapore Exchange, after trading between $75.30 and $78.83. About 293,900 shares changed hands, compared with 410,700 a day earlier. (Yahoo Finance) The move landed as regional markets cooled on a tech-led selloff and broader de-risking. Singapore’s shares fell 0.8% on the day, while investors tracked turbulence tied to U.S. tech and fresh debate over how quickly new AI tools could reshape software and services. “With U.S. tech wobbling, sentiments tend to trickle over
CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Go toTop